抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3175人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852922, encodeId=b57c18529226d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=BMC Cancer：仑伐替尼联合PD-1抑制剂治疗晚期肝细胞癌的真实世界疗效, objectType=article, longId=301506, objectId=0b2e301506ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b2e301506ca, replyNumber=0, likeNumber=99, createdTime=2022-04-26, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b2e301506ca, moduleTitle=BMC Cancer：仑伐替尼联合PD-1抑制剂治疗晚期肝细胞癌的真实世界疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b2e301506ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852886, encodeId=1f3718528861b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NEJM：癌症风险高45%，心血管风险高36%？JAK、TNF抑制剂大PK, objectType=article, longId=295430, objectId=f3f92954303a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3f92954303a, replyNumber=0, likeNumber=114, createdTime=2022-08-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3f92954303a, moduleTitle=NEJM：癌症风险高45%，心血管风险高36%？JAK、TNF抑制剂大PK, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3f92954303a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852974, encodeId=325f18529e422, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, objectType=article, longId=727595, objectId=086be27595c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=086be27595c5, replyNumber=0, likeNumber=82, createdTime=2022-08-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=086be27595c5, moduleTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=086be27595c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852749, encodeId=d4c91852e4989, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=晚期肺癌免疫检查点抑制剂治疗的前景, objectType=article, longId=216881, objectId=3a6e216881b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a6e216881b8, replyNumber=0, likeNumber=89, createdTime=2022-01-30, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a6e216881b8, moduleTitle=晚期肺癌免疫检查点抑制剂治疗的前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a6e216881b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852822, encodeId=24d01852822bf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, objectType=article, longId=221179, objectId=74cf2211e969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cf2211e969, replyNumber=0, likeNumber=73, createdTime=2022-07-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cf2211e969, moduleTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cf2211e969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852797, encodeId=c7531852e978d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, objectType=article, longId=219842, objectId=267d219842d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=267d219842d5, replyNumber=0, likeNumber=85, createdTime=2022-02-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=267d219842d5, moduleTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=267d219842d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852827, encodeId=45f4185282e27, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Br J Dermatol：HSP90抑制剂RGRN-305治疗斑块型银屑病, objectType=article, longId=221385, objectId=293322138531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=293322138531, replyNumber=0, likeNumber=68, createdTime=2022-09-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=293322138531, moduleTitle=Br J Dermatol：HSP90抑制剂RGRN-305治疗斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=293322138531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852696, encodeId=8ec31852696e0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=GUT：质子泵抑制剂不会增加结直肠癌的发病风险, objectType=article, longId=213775, objectId=9aa2213e7536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aa2213e7536, replyNumber=0, likeNumber=70, createdTime=2021-08-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aa2213e7536, moduleTitle=GUT：质子泵抑制剂不会增加结直肠癌的发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aa2213e7536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852825, encodeId=9818185282504, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NEJM： HIF-2α抑制剂Belzutifan有望用于治疗Pacak-Zhuang综合征, objectType=article, longId=221215, objectId=f8152212150a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8152212150a, replyNumber=0, likeNumber=0, createdTime=2022-01-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8152212150a, moduleTitle=NEJM： HIF-2α抑制剂Belzutifan有望用于治疗Pacak-Zhuang综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8152212150a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852897, encodeId=7b82185289e9f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=THER ADV GASTROENTER：质子泵抑制剂会增加胃癌的风险, objectType=article, longId=299693, objectId=289229969362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=289229969362, replyNumber=0, likeNumber=71, createdTime=2022-08-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=289229969362, moduleTitle=THER ADV GASTROENTER：质子泵抑制剂会增加胃癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=289229969362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852691, encodeId=3bc7185269192, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=121, createdTime=2021-10-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852844, encodeId=17161852844eb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=直击耐药性，中国首个第三代BCR-ABL抑制剂奥雷巴替尼获批上市！, objectType=article, longId=292245, objectId=244229224531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=244229224531, replyNumber=0, likeNumber=79, createdTime=2022-06-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=244229224531, moduleTitle=直击耐药性，中国首个第三代BCR-ABL抑制剂奥雷巴替尼获批上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=244229224531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852798, encodeId=55711852e9881, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用, objectType=article, longId=219863, objectId=fc9021986320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc9021986320, replyNumber=0, likeNumber=91, createdTime=2022-08-29, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc9021986320, moduleTitle=Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc9021986320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852811, encodeId=5ed31852811bc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, objectType=article, longId=220495, objectId=dbd22204957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd22204957c, replyNumber=0, likeNumber=58, createdTime=2022-02-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd22204957c, moduleTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd22204957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852905, encodeId=a143185290508, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, objectType=article, longId=300189, objectId=ad87300189e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad87300189e8, replyNumber=0, likeNumber=98, createdTime=2022-03-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad87300189e8, moduleTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad87300189e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852801, encodeId=dd0c1852801d3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=70, createdTime=2022-02-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852758, encodeId=12901852e5878, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Alzheimer's & Dementia：在预防AD方面，TNF-α抑制剂是否比甲氨蝶呤更有效？, objectType=article, longId=217384, objectId=3c3c21e384e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c3c21e384e4, replyNumber=0, likeNumber=127, createdTime=2022-04-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c3c21e384e4, moduleTitle=Alzheimer's & Dementia：在预防AD方面，TNF-α抑制剂是否比甲氨蝶呤更有效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c3c21e384e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852767, encodeId=d38a1852e67bf, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Alzheimer Dementia : 肿瘤坏死因子抑制剂，或可降低痴呆风险, objectType=article, longId=218156, objectId=db4b218156c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db4b218156c6, replyNumber=0, likeNumber=73, createdTime=2021-12-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db4b218156c6, moduleTitle=Alzheimer Dementia : 肿瘤坏死因子抑制剂，或可降低痴呆风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db4b218156c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852724, encodeId=12921852e24b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Cancer Commun：免疫检查点抑制剂治疗结直肠癌的疗效和毒性：真实世界研究, objectType=article, longId=215386, objectId=a81d2153869c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a81d2153869c, replyNumber=0, likeNumber=77, createdTime=2022-03-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a81d2153869c, moduleTitle=Cancer Commun：免疫检查点抑制剂治疗结直肠癌的疗效和毒性：真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a81d2153869c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852870, encodeId=c59418528e00f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle= Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS, objectType=article, longId=294099, objectId=a0a42940993e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0a42940993e, replyNumber=0, likeNumber=113, createdTime=2022-11-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0a42940993e, moduleTitle= Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0a42940993e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

BMC Cancer：仑伐替尼联合PD-1抑制剂治疗晚期肝细胞癌的真实世界疗效

2022-04-26

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NEJM：癌症风险高45%，心血管风险高36%？JAK、TNF抑制剂大PK

2022-08-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果

2022-08-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

晚期肺癌免疫检查点抑制剂治疗的前景

2022-01-30

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究

2022-07-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药

2022-02-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Br J Dermatol：HSP90抑制剂RGRN-305治疗斑块型银屑病

2022-09-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

GUT：质子泵抑制剂不会增加结直肠癌的发病风险

2021-08-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NEJM： HIF-2α抑制剂Belzutifan有望用于治疗Pacak-Zhuang综合征

2022-01-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

THER ADV GASTROENTER：质子泵抑制剂会增加胃癌的风险

2022-08-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2021-10-17

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

直击耐药性，中国首个第三代BCR-ABL抑制剂奥雷巴替尼获批上市！

2022-06-17

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Drugs：SGLT-2抑制剂在治疗非糖尿病性慢性肾病中的作用

2022-08-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性

2022-02-12

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险

2022-03-12

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2022-02-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Alzheimer's & Dementia：在预防AD方面，TNF-α抑制剂是否比甲氨蝶呤更有效？

2022-04-12

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Alzheimer Dementia : 肿瘤坏死因子抑制剂，或可降低痴呆风险

2021-12-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Cancer Commun：免疫检查点抑制剂治疗结直肠癌的疗效和毒性：真实世界研究

2022-03-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Leuk Res：多西帕他钠 (DSTAT)，一种 CXCL12/CXCR4 抑制剂，与阿扎胞苷联合用于治疗低甲基化剂难治性 AML 和 MDS

2022-11-10

科室
- - 订阅+
  - 更多科室
工具
服务